FAPI核素显像在心血管疾病中的研究进展  

Research progress of FAPI radionuclide imaging in cardiovascular diseases

作　　者：韩佳莉 李莉[1] 武萍[1] 宋建波[2] 李思进[1] Han Jiali;Li Li;Wu Ping;Song Jianbo;Li Sijin(Department of Nuclear Medicine,First Hospital of Shanxi Medical University,Taiyuan 030001,China;Department of Cancer Center,Third Hospital of Shanxi Medical University,Taiyuan 030032,China)

机构地区：[1]山西医科大学第一医院核医学科,太原030001 [2]山西医科大学第三医院肿瘤中心,太原030032

出　　处：《中华核医学与分子影像杂志》2024年第4期244-248,共5页Chinese Journal of Nuclear Medicine and Molecular Imaging

基　　金：国家自然科学基金(81901785)。

摘　　要：心肌纤维化是多种心血管疾病发生发展的重要病理过程,与患者预后密切相关。活化的成纤维细胞(CFs)是其中主要的效应细胞,其表面特异性高表达成纤维细胞激活蛋白(FAP)。核素标记的FAP抑制剂(FAPIs)能与FAP特异性结合,在体可视化活化的CFs,在多种心血管疾病的早期诊断、预后预测及干预指导中表现出初步的临床应用价值。该文就核素标记的FAPIs在心血管疾病显像中的研究进展进行综述。Myocardial fibrosis is an important pathological process in the development of cardiovascular diseases,which is closely related to the prognosis of patients.Activated cardiac fibroblasts(CFs)are the main effector cells,whose surface specifically overexpress fibroblast activation protein(FAP).Radionuclide-labeled FAP inhibitors(FAPIs)can specifically bind to FAP to visualize activated CFs in vivo,showing preliminary clinical application in the early diagnosis,prognosis prediction and interventional guidance of various cardiovascular diseases.This article reviews the progress of researches on the application of radionuclide-labeled FAPIs in cardiovascular diseases imaging.

关 键 词：心血管疾病 拮抗剂和抑制剂 膜蛋白质类 成纤维细胞 发展趋势 

分 类 号：R54[医药卫生—心血管疾病] R817.4[医药卫生—内科学]